Gastrointestinal (GI) cancer consists of cancer from various organs including colorectal, liver, pancreas, gastric, and esophagus. GI cancers are the leading cause of cancer-related deaths worldwide and there are severe unmet medical needs to control the disease. Recently, treatment for solid tumors targeting the immune system has achieved success in gastrointestinal cancer. However, many questions about immunotherapy call for more research to answer, such as, the unknown regulation of immune response within tumor microenvironment. Understanding the immune response in cancer development and treatment is important to guide personal medicine and uncover potential molecules as novel immune biomarkers or targets in the future.
The goal of this Research Topic is to publish novel research discovering the role of immune response during development and treatment of GI cancer. We focus on the immune response in different cancer stages or types of treatment, approaches ranging from physiology of immune response in cancer development to clinical immune biomarkers in cancer treatment that may significantly contribute to shedding light on the immune regulation of GI cancer.
Authors are welcome to submit original articles and reviews that seek to better characterize the regulation of immune response of GI cancer. Contributions investigating the regulation of immune response at the molecular and cellular level, as well as clinical trials, are also welcomed. In silico data analysis needs to be verified with in vitro/in vivo experiment.
Some potential themes of interest covering but not limited to:
• Advances in immune response during GI cancer development
• Advances in local or peripheral immune regulation during GI cancer treatment
• Advances in immune related adverse effects during GI cancer treatment
• Novel immune biomarkers related to immunotherapies
• Novel immune biomarkers related to chemotherapy, radiotherapy, targeted therapy or in combination.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gastrointestinal (GI) cancer consists of cancer from various organs including colorectal, liver, pancreas, gastric, and esophagus. GI cancers are the leading cause of cancer-related deaths worldwide and there are severe unmet medical needs to control the disease. Recently, treatment for solid tumors targeting the immune system has achieved success in gastrointestinal cancer. However, many questions about immunotherapy call for more research to answer, such as, the unknown regulation of immune response within tumor microenvironment. Understanding the immune response in cancer development and treatment is important to guide personal medicine and uncover potential molecules as novel immune biomarkers or targets in the future.
The goal of this Research Topic is to publish novel research discovering the role of immune response during development and treatment of GI cancer. We focus on the immune response in different cancer stages or types of treatment, approaches ranging from physiology of immune response in cancer development to clinical immune biomarkers in cancer treatment that may significantly contribute to shedding light on the immune regulation of GI cancer.
Authors are welcome to submit original articles and reviews that seek to better characterize the regulation of immune response of GI cancer. Contributions investigating the regulation of immune response at the molecular and cellular level, as well as clinical trials, are also welcomed. In silico data analysis needs to be verified with in vitro/in vivo experiment.
Some potential themes of interest covering but not limited to:
• Advances in immune response during GI cancer development
• Advances in local or peripheral immune regulation during GI cancer treatment
• Advances in immune related adverse effects during GI cancer treatment
• Novel immune biomarkers related to immunotherapies
• Novel immune biomarkers related to chemotherapy, radiotherapy, targeted therapy or in combination.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
